These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Jun 6, 2016
ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a drug development company advancing targeted therapeutics for patients with cancer, today announced interim results from the Wolverine Phase 2 trial of...
Jun 1, 2016
ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel targeted therapeutics, today announced it has appointed Dr. Christian Hassig as Senior Vice President,...
May 26, 2016
- Small molecule kinase inhibitor AS-141 positioned for clinical trials in 2017 - - CDC7 is an important regulator of DNA replication and DNA damage response - VANCOUVER, May 26, 2016 /CNW/ -...
May 18, 2016
- ProNAi to hold Analyst & Investor Event at 7:00am CT on June 6th - - ProNAi to Present at Jefferies 2016 Healthcare Conference in New York on June 9th – VANCOUVER, May 18, 2016 /CNW/ - ProNAi...
May 10, 2016
ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel therapeutics for patients with cancer and hematological diseases, today reported its financial and...